{
    "nct_id": "NCT06315491",
    "official_title": "A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer",
    "inclusion_criteria": "* Subjects must have histologically- or cytologically-diagnosed epithelial high-grade serous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer that is refractory to prior therapy and must have platinum-resistant disease defined as:\n\n  * Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring â‰¤ 26 weeks after their last dose of platinum.\n  * Patients who have progressed following a second course of a platinum based regimen.\n  * Subjects may have up to 2 additional systemic regimens for advanced or metastatic disease. Maintenance regimens (e.g., with a PARP inhibitor or bevacizumab) are not considered separate regimens.\n* Age greater than or equal to 18 years at the time of signing the informed consent form (ICF).\n* Has measurable disease per RECIST 1.1.\n* Has provided written informed consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate liver, renal, hematologic, pulmonary and coagulation function.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.\n* Subjects who are currently receiving any other anticancer or investigational agent(s).\n* Clinically significant intercurrent disease.\n* Active human immunodeficiency virus (HIV) infection.\n* Active hepatitis B or C infection.",
    "miscellaneous_criteria": ""
}